Kala Pharmaceuticals Inc. Stock
Kala Pharmaceuticals Inc. took a tumble today and lost -€0.047 (-7.740%).
We see a rather positive sentiment for Kala Pharmaceuticals Inc. with 12 Buy predictions and 1 Sell predictions.
With a target price of 13 € there is potential for a 2219.36% increase which would mean more than doubling the current price of 0.56 € for Kala Pharmaceuticals Inc..
Our community identified positive and negative aspects for Kala Pharmaceuticals Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Kala Pharmaceuticals Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Kala Pharmaceuticals Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Kala Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Kala Pharmaceuticals Inc. | -7.740% | -20.171% | 2.705% | -89.200% | -90.567% | -85.110% | -99.806% |
| Ardelyx Inc. | -1.590% | 2.840% | 4.881% | 6.187% | 6.465% | 184.469% | -6.409% |
| Krystal Biotech | 0.720% | 3.678% | 18.962% | 33.718% | 37.057% | 193.803% | - |
| Evolus Inc | 1.750% | -1.724% | -7.317% | -46.729% | -45.714% | -13.636% | 73.622% |
Comments
KALA BIO (NASDAQ:KALA) had its price target raised by analysts at HC Wainwright from $12.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KALA provided by MarketBeat
KALA BIO (NASDAQ:KALA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $15.00 to $33.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KALA provided by MarketBeat
KALA BIO (NASDAQ:KALA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $30.00 price target on the stock.
Show more
Ratings data for KALA provided by MarketBeat